Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? | Zendy

Arushi Khurana | Zendy; Raphael Mwangi | Zendy; Grzegorz S. Nowakowski | Zendy; Thomas M. Habermann | Zendy; Stephen M. Ansell | Zendy; Betsy LaPlant | Zendy; Brian K. Link | Zendy; James R. Cerhan | Zendy; Matthew J. Maurer | Zendy; Thomas E. Witzig | Zendy

Open Access

Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Author(s) -

Arushi Khurana,

Raphael Mwangi,

Grzegorz S. Nowakowski,

Thomas M. Habermann,

Stephen M. Ansell,

Betsy LaPlant,

Brian K. Link,

James R. Cerhan,

Matthew J. Maurer,

Thomas E. Witzig

Publication year - 2021

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.01935

Subject(s) - medicine , diffuse large b cell lymphoma , hazard ratio , clinical trial , lymphoma , oncology , surgery , confidence interval

Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function-based eligibility criteria on this effect and clinical trial exclusion is less well-understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research